PMID- 36503735
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20221226
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 44
IP  - 12
DP  - 2022 Dec
TI  - Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall 
      Survival Based on Reconstructed Patient-Level Data.
PG  - 1626-1632
LID - S0149-2918(22)00377-0 [pii]
LID - 10.1016/j.clinthera.2022.11.002 [doi]
AB  - PURPOSE: Chimeric antigen receptor (CAR) T-cell products (eg, tisagenlecleucel 
      [tisa], axicabtagene ciloleucel [axi]) have been used in patients with 
      relapsed/refractory large B-cell lymphoma (LBCL) and in adult patients with acute 
      lymphoblastic leukemia (ALL). After the recent publication of long-term follow-up 
      data in LBCL, reviewing the evidence on this topic is worthwhile. The aim of the 
      present work was to study the pattern of overall survival (OS) reported for CAR 
      T-cell products in LBLC and ALL. METHODS: A standard literature search was 
      performed. OS was studied through an artificial intelligence technique (the Shiny 
      method) that reconstructs individual patient data from published Kaplan-Meier 
      curves. Standard statistics along with indirect comparisons were performed on 
      these reconstructed data. Indirect comparisons focused on CAR T cells versus 
      chemotherapy in LBCL and ALL; tisa and axi were further indirectly compared in 
      LBCL. FINDINGS: Seven trials were included (4 for LBCL, 3 for ALL). Other 
      populations were selected as control groups. The main results of our analysis 
      were: (1) the survival advantage of CAR T cells is greater in adult patients with 
      ALL than in patients with LBCL; and (2) for LBCL, the survival gain is more 
      substantial for axi compared with tisa. IMPLICATIONS: Our results are helpful to 
      define the place in therapy of CAR T cells in these 2 disease conditions and also 
      suggest preliminary estimates of cost-effectiveness. One strength of our analysis 
      is that extensive information was available for the treatment options included in 
      indirect comparisons. The main weakness is the inability of the Shiny method to 
      perform multivariate analyses.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Messori, Andrea
AU  - Messori A
AD  - HTA Unit, Regione Toscana, Firenze, Italy. Electronic address: 
      andrea.messori.it@gmail.com.
FAU - Chiumente, Marco
AU  - Chiumente M
AD  - Direzione Scientifica, Societa Italiana di Farmacia Clinica e Terapia, Milano, 
      Italy.
FAU - Mengato, Daniele
AU  - Mengato D
AD  - Azienda Ospedale di Padova, Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221209
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Receptors, Chimeric Antigen
MH  - Artificial Intelligence
MH  - Antigens, CD19
MH  - Immunotherapy, Adoptive/methods
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - T-Lymphocytes
MH  - *Biological Products
OTO - NOTNLM
OT  - CAR T cell
OT  - acute lymphoblastic leukemia
OT  - axicabtagene ciloleucel
OT  - large B-cell lymphoma
OT  - overall survival
OT  - tisagenlecleucel
COIS- Declaration of Interest None.
EDAT- 2022/12/13 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/12/12 09:37
PHST- 2022/06/05 00:00 [received]
PHST- 2022/10/17 00:00 [revised]
PHST- 2022/11/02 00:00 [accepted]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/12/12 09:37 [entrez]
AID - S0149-2918(22)00377-0 [pii]
AID - 10.1016/j.clinthera.2022.11.002 [doi]
PST - ppublish
SO  - Clin Ther. 2022 Dec;44(12):1626-1632. doi: 10.1016/j.clinthera.2022.11.002. Epub 
      2022 Dec 9.